Categories AlphaGraphs, Earnings, Health Care

Abiomed’s (ABMD) revenue increases 13% in Q2 on higher usage of Impella; reiterates 2020 outlook

Abiomed (NASDAQ: ABMD) reported a 13% growth in second quarter 2020 revenue, boosted by the increased usage of its Impella heart pumps. However, revenue of $205 million in the second quarter missed the market’s view of $206.45 million. The company also reiterated its fiscal 2020 revenue outlook. Shares of Abiomed, which ended down 1.72% at $181.77 yesterday, rose about 3% in the pre-market trading hours.

Abiomed’s (ABMD) revenue increases 13% in Q2 on higher usage of Impella; reiterates 2020 outlook

The medical device maker reported GAAP net income of $13.1 million, or $0.28 per share for the second quarter of 2020, which includes a $34.5 million, or $0.75 per share, unrealized loss from its investment in Shockwave. This compares to GAAP net income of $50.1 million or $1.09 per share in the second quarter of fiscal 2019.

U.S. revenue increased 9% to $172 million in the second quarter ended September 30, 2019. Outside the US revenue jumped 40% to $33 million, driven primarily by a 135% increase in Japan revenue. Early this month, the 1,000th patient has been treated with the Impella heart pump in Japan.

Abiomed had introduced Impella 5.5 with SmartAssist in the U.S. through a controlled rollout at hospitals with established heart recovery protocols. Today, the company announced that first 10 patients treated with Impella 5.5 with SmartAssist in the U.S.

The Danvers, Massachusetts-based company maintained its fiscal year 2020 revenue and operating margin guidance. Revenue is expected to grow in the range of 15% to 20% over the prior year to a range of $885 million to $925 million. FY20 GAAP operating margin is estimated to be in the range of 28% to 30%.

Also Read:  American Eagle Outfitters (AEO) Earnings: 2Q20 Key Numbers

“We have made progress on our key initiatives in the quarter, but we still have more work to do. Our innovation and ability to improve clinical outcomes remains the driver for Impella adoption through a function of training, data and time,” said CEO Michael Minogue.

ABMD stock, which plunged to a fresh yearly low ($155.02) early this month, dropped both in the year-to-date and past 12-month periods by 44% and 45%, respectively.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results

One thought on “Abiomed’s (ABMD) revenue increases 13% in Q2 on higher usage of Impella; reiterates 2020 outlook

Comments are closed.